These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 35337140)
21. Optimization of Labeling PSMA Eppard E; Homann T; de la Fuente A; Essler M; Rösch F J Nucl Med; 2017 Mar; 58(3):432-437. PubMed ID: 28082433 [TBL] [Abstract][Full Text] [Related]
22. Radiochemistry and Preclinical PET Imaging of Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
24. Automated production of [ Garcia-Arguello SF; Lopez-Lorenzo B; Ruiz-Cruces R J Labelled Comp Radiopharm; 2019 Mar; 62(3):146-153. PubMed ID: 30672007 [TBL] [Abstract][Full Text] [Related]
26. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344 [TBL] [Abstract][Full Text] [Related]
27. Preparation and clinical translation of Vats K; Agrawal K; Sharma R; Sarma HD; Satpati D; Dash A Medchemcomm; 2019 Dec; 10(12):2111-2117. PubMed ID: 32190233 [TBL] [Abstract][Full Text] [Related]
28. Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [ Migliari S; Sammartano A; Scarlattei M; Serreli G; Ghetti C; Cidda C; Baldari G; Ortenzia O; Ruffini L ACS Omega; 2017 Oct; 2(10):7120-7126. PubMed ID: 29520394 [No Abstract] [Full Text] [Related]
29. Preparation of Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844 [TBL] [Abstract][Full Text] [Related]
31. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT. Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735 [TBL] [Abstract][Full Text] [Related]
33. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
34. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512 [No Abstract] [Full Text] [Related]
35. Diagnostic performance of Hoffmann MA; Miederer M; Wieler HJ; Ruf C; Jakobs FM; Schreckenberger M Oncotarget; 2017 Dec; 8(67):111073-111083. PubMed ID: 29340038 [TBL] [Abstract][Full Text] [Related]
36. Clinical translation of a PSMA inhibitor for Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503 [TBL] [Abstract][Full Text] [Related]
38. The impact of [ Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670 [TBL] [Abstract][Full Text] [Related]
39. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting. Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611 [TBL] [Abstract][Full Text] [Related]
40. In-House Preparation and Quality Control of Ac-225 Prostate-Specific Membrane Antigen-617 for the Targeted Alpha Therapy of Castration-Resistant Prostate Carcinoma. Thakral P; Simecek J; Marx S; Kumari J; Pant V; Sen IB Indian J Nucl Med; 2021; 36(2):114-119. PubMed ID: 34385780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]